CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,967,151 | -16.5% | 107,818 | +3.0% | 0.68% | -19.8% |
| Q2 2023 | $3,552,980 | -2.1% | 104,715 | +3.8% | 0.84% | -2.1% |
| Q1 2023 | $3,629,986 | -22.8% | 100,889 | -4.4% | 0.86% | -22.7% |
| Q4 2022 | $4,704,720 | +56.3% | 105,558 | -1.5% | 1.11% | +53.3% |
| Q3 2022 | $3,011,000 | +5.0% | 107,128 | +0.7% | 0.73% | +7.2% |
| Q2 2022 | $2,868,000 | -6.5% | 106,368 | +18.1% | 0.68% | +9.0% |
| Q1 2022 | $3,067,000 | -7.8% | 90,048 | +4.6% | 0.62% | -11.3% |
| Q4 2021 | $3,325,000 | -16.5% | 86,052 | +16.7% | 0.70% | -22.5% |
| Q3 2021 | $3,980,000 | +51.3% | 73,716 | -6.3% | 0.90% | +51.8% |
| Q2 2021 | $2,631,000 | +68.8% | 78,679 | +4.0% | 0.60% | +48.8% |
| Q1 2021 | $1,559,000 | +232.4% | 75,676 | +182.9% | 0.40% | +210.1% |
| Q4 2020 | $469,000 | +24.1% | 26,749 | +5.0% | 0.13% | +9.3% |
| Q3 2020 | $378,000 | +51.8% | 25,466 | +33.1% | 0.12% | +26.9% |
| Q2 2020 | $249,000 | +822.2% | 19,134 | +68.8% | 0.09% | +745.5% |
| Q1 2020 | $27,000 | – | 11,332 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |